Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
暂无分享,去创建一个
P. Smits | Elvin Kedhi | E. Mcfadden | Eugene McFadden | Elvin Kedhi | Kaiyum Sheik Joesoef | Jochem Wassing | Pieter Cornelis Smits | J. Wassing | K. S. Joesoef
[1] R. Virmani,et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.
[2] F. Eberli,et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.
[3] D. Baim,et al. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial. , 2007, Journal of the American College of Cardiology.
[4] Antonio Colombo,et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.
[5] P. Serruys,et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. , 2009, Journal of the American College of Cardiology.
[6] Gregg W. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .
[7] Gary G. Koch,et al. Categorical Data Analysis Using The SAS1 System , 1995 .
[8] Marco Valgimigli,et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. , 2005, Journal of the American College of Cardiology.
[9] F. Eberli,et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. , 2008, European heart journal.
[10] A. Kastrati,et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.
[11] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[12] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[13] P. Serruys,et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[14] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[15] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[16] P. Fitzgerald,et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.
[17] Douglas G Altman,et al. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.
[18] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[19] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .